ProKidney (PROK) Financials

ProKidney’s latest quarter shows a company with a large cash cushion, but also a business model that is still heavily dependent on investment income and external funding while operating losses remain substantial. In Q1 2026, revenue was only $226,000, while net loss attributable to common shareholders was $20.0 million. The company ended the quarter with $101.9 million in cash and $123.0 million in short-term investments, giving it meaningful liquidity even as it continues to burn cash.

What stands out most is the balance sheet strength versus the operating profile. ProKidney’s cash and investments totaled about $224.9 million at March 31, 2026, down from roughly $272.3 million at the end of Q3 2025. That decline reflects ongoing operating losses and continued spending on R&D and overhead, although the company still appears well-capitalized relative to near-term obligations.

• Cash and short-term investments remained strong at about $224.9 million in Q1 2026, providing liquidity runway.
• Operating cash flow improved sequentially, with net cash used in operations narrowing to -$41.7 million from -$32.5 million in Q4 2025 and -$26.6 million in Q3 2025, though still negative.
• Investment income was meaningful, with $2.3 million in interest and investment income in Q1 2026, helping offset losses.
• The company continues to hold a sizable asset base, including $54.4 million of net PP&E and $234.9 million in current assets.
• Total liabilities were relatively modest at $29.7 million, compared with assets of $292.8 million.
• R&D spending remained elevated at $33.8 million in Q1 2026, consistent with a development-stage biotech focused on pipeline progress.
• Revenue was minimal at only $226,000, indicating the company is still far from meaningful commercialization.
• Selling, general and administrative expense was also high at $11.3 million, adding to the cash burn.
• ProKidney reported a net loss of $42.6 million in Q1 2026, reflecting that the business is still not profitable.
• Total common equity remained deeply negative at -$1.02 billion, largely because of the company’s capital structure and accumulated losses.

Looking at the last several quarters, the trend is mixed. Revenue has been essentially flat and tiny, hovering around $217,000 to $230,000 per quarter, so there has been no real top-line acceleration yet. Meanwhile, operating expenses remain very high, though there was some quarter-to-quarter moderation in Q1 2026 versus late 2025. That helped trim the net loss slightly from Q4 2025’s -$40.9 million to -$42.6 million in Q1 2026, but the company is still far from breakeven.

On the cash flow side, ProKidney has relied heavily on its investment portfolio and financing activities. In prior quarters, investing cash flow was often positive because maturities and sales of investments exceeded new purchases, which helped offset operating losses. In Q1 2026, investing activities contributed $34.8 million, but that is not a sustainable long-term source of funding. The company’s ability to keep funding operations will depend on its cash reserves, capital markets access, and eventual clinical or commercial progress.

Bottom line: ProKidney currently looks like a well-funded development-stage biotech with a solid liquidity position, but the fundamental challenge remains the same: very small revenue, heavy R&D spending, and continued losses. For retail investors, the key question is whether management can translate that cash runway into meaningful clinical or commercial milestones before dilution or additional financing becomes necessary.